Cancer BiologybioRxivPreprint
Abbapolin inhibitors of the PLK1 PBD as Prostate Cancer Therapeutics, in vivo activity and synergy with androgen therapy
George Merhej, Gurusankar Ramamoorthy, Danda P. Chapagai…·Campbell McInnes
This study develops and characterizes abbapolins, non-peptidic PLK1 PBD inhibitors, showing in vivo efficacy against prostate cancer and synergy with enzalutamide.
DOI 10.64898/2026.07.02.736204